<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Transgene Biotek Ltd has submitted a filing to BSE confirming that it does not meet the criteria to be classified as a 'Large Corporate' under the SEBI circular dated November 26, 2018 and the BSE circular dated April 11, 2019. The classification is based on thresholds related to outstanding borrowing and total assets. The company has explicitly stated it does not qualify under Para 2.2 of the said SEBI circular. The disclosure was signed by Dr K Koteswara Rao, Chairman & Managing Director, on April 19, 2025. This is a routine annual compliance filing required of all listed entities.
This is a routine regulatory disclosure with no material impact on shareholders or the stock price. It simply confirms the company is below the size threshold that would subject it to additional borrowing and disclosure obligations for large corporates.